经会阴与经直肠前列腺穿刺诊断前列腺癌:随机对照试验系统评价与Meta分析
该系统评价与Meta分析纳入5项2010年后发表的随机对照试验、共3072名疑似前列腺癌男性,比较经会阴穿刺(TP-Bx)与经直肠穿刺(TR-Bx)的感染并发症和诊断表现。贝叶斯随机效应模型显示,TP-Bx感染并发症风险更低(pOR 0.38,95%CrI 0.11-0.90),且该组未使用抗生素预防;两组临床显著前列腺癌检出无差异(pOR 1.01,95%CrI 0.65-1.51)。作者认为在可行时TP-Bx应作为首选穿刺路径。
要点
- TP-Bx感染并发症风险低于TR-Bx(pOR 0.38,95%CrI 0.11-0.90),且无需抗生素预防。
- 两组临床显著前列腺癌检出无差异(pOR 1.01,95%CrI 0.65-1.51)。
- TP-Bx术后疼痛评分更高、手术时间略长,但临床意义不确定。
核心结论
- TP-Bx感染率更低且无需抗生素预防,前列腺癌检出与TR-Bx相当,尽管不适感和操作时间轻度增加。
- 在可行情况下,TP-Bx应被视为首选的穿刺路径。
研究设计与样本
- 系统检索MEDLINE、Embase、CINAHL、Cochrane CENTRAL和ClinicalTrials.gov,检索日期为2025年4月1日,遵循PRISMA指南。
- 纳入2010年后发表的比较TP-Bx与TR-Bx的随机对照试验,共5项、3072名男性(TP-Bx 1547例,TR-Bx 1525例)。
- 绝大多数受试者为初次穿刺且接受mpMRI靶向穿刺,采用贝叶斯随机效应Meta分析,注册号PROSPERO CRD42024522857。
主要发现
- TP-Bx感染并发症风险更低(pOR 0.38,95%CrI 0.11-0.90),该组未使用抗生素预防。
- TP-Bx需干预的出血风险可能更低(pOR 0.54,95%CrI 0.23-1.14),但估计不精确。
- 临床显著前列腺癌检出无差异(pOR 1.01,95%CrI 0.65-1.51),非临床显著前列腺癌检出亦无差异(pOR 1.12,95%CrI 0.63-2.18)。
- 急性尿潴留风险无差异(pOR 0.66,95%CrI 0.26-1.58)。
- 两项研究报告TP-Bx术后疼痛评分更高,两项研究报告手术时间略长,但差异的临床相关性不确定。
关键数值与推荐
- 主要结局为感染并发症率,次要结局包括临床显著和非临床显著前列腺癌检出、尿潴留、出血和患者报告疼痛。
- TP-Bx组未使用抗生素预防仍与更低的感染并发症风险相关(pOR 0.38,95%CrI 0.11-0.90)。
临床怎么用
- 在mpMRI时代,对疑似前列腺癌男性可优先考虑TP-Bx以降低感染风险。
- TP-Bx可不依赖抗生素预防,但需告知患者术后疼痛可能更明显、操作时间可能略长。
- 穿刺路径选择应综合感染风险、诊断需求和患者耐受性个体化决定。
局限性
- 纳入研究仅5项,样本量有限,部分结局估计不精确。
- 出血和疼痛等次要结局的临床相关性不确定。
- 绝大多数受试者为初次穿刺且接受mpMRI靶向穿刺,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There has been debate for decades whether transperineal prostate biopsy (TP-Bx) or transrectal biopsy (TR-Bx) is the optimal route. Randomized controlled trials (RCTs) conducted in the contemporary era provide new evidence for reassessment of the comparative infectious risks and diagnostic performance, particularly relevant given rising antibiotic resistance and evolving prostate cancer (PC) diagnostic paradigms. Our aim was to compare infectious complications, detection of clinically significant PC (csPC), and other biopsy-related outcomes between TP-Bx and TR-Bx in men with suspected PC undergoing biopsy in the multiparametric magnetic resonance imaging (mpMRI) era. METHODS: A systematic literature search (MEDLINE, Embase, CINAHL, Cochrane CENTRAL, and ClinicalTrials.gov) was conducted on April 1, 2025 in accordance with PRISMA guidelines. RCTs comparing TP-Bx and TR-Bx published after 2010 were included. Data were independently extracted by two reviewers using a standardized protocol (PROSPERO CRD42024522857). Risk of bias was assessed using the updated Cochrane tool. We performed a Bayesian random-effects meta-analysis, using models specifically suited for few-study settings and rare events. Sensitivity analyses were performed. The primary outcome was the infectious complication rate. Secondary outcomes included detection of csPC and non-clinically significant PC (ncsPC), urinary retention, bleeding, and patient-reported pain. KEY FINDINGS AND LIMITATIONS: Five RCTs involving 3072 men were included (1547 TP-Bx, 1525 TR-Bx). The vast majority were Bx-naïve and underwent mpMRI-targeted Bx. TP-Bx was associated with lower risk of infectious complications (pooled odds ratio [pOR] 0.38, 95% credible interval [CrI] 0.11-0.90), despite no antibiotic prophylaxis in this arm. Results also suggest a lower risk of bleeding requiring intervention with TP-Bx (pOR 0.54, 95% CrI 0.23-1.14), although the estimates were imprecise. There was no evidence of a difference in detection of csPC (pOR 1.01, 95% CrI 0.65-1.51) or ncsPC (pOR 1.12, 95% CrI 0.63-2.18), or in acute urinary retention (pOR 0.66, 95% CrI 0.26-1.58). Two studies assessing pain reported higher post-Bx pain scores for TP-Bx, and two studies reported slightly longer operating times, although these differences were of uncertain clinical relevance. CONCLUSIONS AND CLINICAL IMPLICATIONS: TP-Bx offers lower infection rates with no antibiotic prophylaxis needed and equivalent PC detection in comparison to TR-Bx, despite minimal increases in discomfort and procedure time. When feasible, TP-Bx should be considered the preferred Bx approach.
引用
- Marra G, Bazzurro F, Dematteis A, et al. Transperineal Versus Transrectal Biopsy for Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Oncol. 2026. PMID: 41667335. doi:10.1016/j.euo.2026.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。